PL366119A1 - Treatment of anxiety disorders - Google Patents

Treatment of anxiety disorders

Info

Publication number
PL366119A1
PL366119A1 PL01366119A PL36611901A PL366119A1 PL 366119 A1 PL366119 A1 PL 366119A1 PL 01366119 A PL01366119 A PL 01366119A PL 36611901 A PL36611901 A PL 36611901A PL 366119 A1 PL366119 A1 PL 366119A1
Authority
PL
Poland
Prior art keywords
treatment
anxiety disorders
anxiety
disorders
Prior art date
Application number
PL01366119A
Other languages
English (en)
Polish (pl)
Inventor
Holly Read Thomasson
David Michelson
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL366119A1 publication Critical patent/PL366119A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL01366119A 2000-11-15 2001-11-06 Treatment of anxiety disorders PL366119A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24901000P 2000-11-15 2000-11-15
US26536201P 2001-01-31 2001-01-31

Publications (1)

Publication Number Publication Date
PL366119A1 true PL366119A1 (en) 2005-01-24

Family

ID=26939750

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01366119A PL366119A1 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders

Country Status (16)

Country Link
EP (1) EP1395253A2 (no)
JP (1) JP2004529073A (no)
KR (1) KR20030051812A (no)
CN (1) CN1822825A (no)
AU (1) AU2002217757A1 (no)
BR (1) BR0115301A (no)
CA (1) CA2426069A1 (no)
CZ (1) CZ20031339A3 (no)
EA (1) EA200300567A1 (no)
HR (1) HRP20030384A2 (no)
IL (1) IL155874A0 (no)
MX (1) MXPA03004190A (no)
NO (1) NO20032156D0 (no)
PL (1) PL366119A1 (no)
SK (1) SK5422003A3 (no)
WO (1) WO2002040006A2 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032380A3 (en) * 2001-03-06 2004-03-17 Eli Lilly And Company Inhibitor of monoamine uptake
CN1674907A (zh) * 2002-08-14 2005-09-28 法玛西亚普强责任有限公司 瑞波西汀在治疗热潮红中的用途
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
WO2009089479A2 (en) 2008-01-09 2009-07-16 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
US20120220665A1 (en) * 2009-11-03 2012-08-30 Mayo Foundation For Medical Education And Research Inhibiting Neurotransmitter Reuptake
WO2011056788A2 (en) * 2009-11-03 2011-05-12 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
WO2014159251A2 (en) 2013-03-14 2014-10-02 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
JP2022519541A (ja) * 2019-02-01 2022-03-24 ホフマン・テクノロジーズ・エルエルシー 不安関連障害を処置するための組成物および方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2931997A (en) * 1996-05-07 1997-11-26 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
ES2246485T3 (es) * 1999-07-01 2006-02-16 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar la incontinencia.

Also Published As

Publication number Publication date
IL155874A0 (en) 2003-12-23
CZ20031339A3 (cs) 2003-10-15
CN1822825A (zh) 2006-08-23
NO20032156L (no) 2003-05-13
WO2002040006A3 (en) 2003-12-24
AU2002217757A1 (en) 2002-05-27
JP2004529073A (ja) 2004-09-24
MXPA03004190A (es) 2003-09-22
HRP20030384A2 (en) 2003-08-31
BR0115301A (pt) 2004-12-14
CA2426069A1 (en) 2002-05-23
WO2002040006A2 (en) 2002-05-23
EA200300567A1 (ru) 2004-10-28
EP1395253A2 (en) 2004-03-10
KR20030051812A (ko) 2003-06-25
NO20032156D0 (no) 2003-05-13
SK5422003A3 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
GB0007193D0 (en) Treatment of movrmrnt disorders
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
IL155433A0 (en) Treatment of t cell disorders
AU2002360555A8 (en) Treatment of genitourinary tract disorders
IL155874A0 (en) Treatment of anxiety disorders
IL150479A0 (en) Treatment of psoriasis
IL150290A0 (en) The use of mirtazapine for the treatment of sleep disorders
IL140540A0 (en) Treatment of anxiety disorders
SI1468686T1 (sl) S-metil-dihidro-ziprazidon za zdravljenje psihiatricnih motenj
IL151493A0 (en) Use of dermaciclane for the treatment of anxiety and depression
EP1303281A4 (en) METHODS OF TREATMENT
GB0017951D0 (en) Treatment of movement disorders
GB0010496D0 (en) Treatment of conditions of the central nervous system
HUP0301798A3 (en) Treatment of eating disorders using carboxyalkylethers
GB0003228D0 (en) Treatment of GI disorders
GB0029955D0 (en) Treatment of neuropsychiatric disorders
GB0125371D0 (en) Treatment of movement disorders
GB0021060D0 (en) Treatment of functional gastrointestinal disorders
GB9924942D0 (en) Treatment of movement disorders
GB0014904D0 (en) Methods of treatment
GB0013928D0 (en) Methods of treatment
GB0004998D0 (en) The treatment of functional gastrointestinal disorders
GB0024704D0 (en) Treatment of hyperproliferative skin disorders
GB0219811D0 (en) Treatment of excreta

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)